Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | steroid-5-alpha-reductase, alpha polypeptide 1 (3-oxo-5 alpha-steroid delta 4-dehydrogenase alpha 1) | Starlite/ChEMBL | References |
Homo sapiens | cytochrome P450, family 17, subfamily A, polypeptide 1 | Starlite/ChEMBL | References |
Homo sapiens | steroid-5-alpha-reductase, alpha polypeptide 2 (3-oxo-5 alpha-steroid delta 4-dehydrogenase alpha 2) | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | Cytochrome P450 family protein | cytochrome P450, family 17, subfamily A, polypeptide 1 | 508 aa | 468 aa | 25.2 % |
Plasmodium falciparum | 3-oxo-5-alpha-steroid 4-dehydrogenase, putative | steroid-5-alpha-reductase, alpha polypeptide 1 (3-oxo-5 alpha-steroid delta 4-dehydrogenase alpha 1) | 259 aa | 254 aa | 25.6 % |
Brugia malayi | Synaptic glycoprotein SC2 | steroid-5-alpha-reductase, alpha polypeptide 2 (3-oxo-5 alpha-steroid delta 4-dehydrogenase alpha 2) | 254 aa | 208 aa | 28.9 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | hypothetical protein | 0.0377 | 0.127 | 0.127 |
Trypanosoma brucei | dihydrofolate reductase-thymidylate synthase | 0.103 | 0.4267 | 1 |
Trypanosoma cruzi | 3-oxo-5-alpha-steroid 4-dehydrogenase, putative | 0.0377 | 0.127 | 0.2977 |
Schistosoma mansoni | bifunctional dihydrofolate reductase-thymidylate synthase | 0.0159 | 0.0267 | 0.0267 |
Loa Loa (eye worm) | thymidylate synthase | 0.0159 | 0.0267 | 0.0267 |
Mycobacterium ulcerans | thymidylate synthase | 0.0159 | 0.0267 | 0.0267 |
Brugia malayi | 3-oxo-5-alpha-steroid 4-dehydrogenase 1 | 0.0377 | 0.127 | 0.127 |
Onchocerca volvulus | 0.0159 | 0.0267 | 1 | |
Leishmania major | 3-oxo-5-alpha-steroid 4-dehydrogenase-like protein | 0.0377 | 0.127 | 0.2977 |
Schistosoma mansoni | dihydrofolate reductase | 0.2278 | 1 | 1 |
Leishmania major | dihydrofolate reductase-thymidylate synthase | 0.103 | 0.4267 | 1 |
Trypanosoma cruzi | 3-oxo-5-alpha-steroid 4-dehydrogenase, putative | 0.0377 | 0.127 | 0.2977 |
Mycobacterium ulcerans | hypothetical protein | 0.0377 | 0.127 | 0.127 |
Entamoeba histolytica | steroid 5-alpha reductase, putative | 0.0377 | 0.127 | 0.5 |
Mycobacterium leprae | PROBABLE THYMIDYLATE SYNTHASE THYA (TS) (TSASE) | 0.0159 | 0.0267 | 0.0267 |
Trichomonas vaginalis | 3-oxo-5-alpha-steroid 4-dehydrogenase, putative | 0.0377 | 0.127 | 1 |
Trichomonas vaginalis | 3-oxo-5-alpha-steroid 4-dehydrogenase, putative | 0.0377 | 0.127 | 1 |
Mycobacterium tuberculosis | Probable thymidylate synthase ThyA (ts) (TSASE) | 0.0159 | 0.0267 | 0.0267 |
Echinococcus granulosus | thymidylate synthase | 0.0159 | 0.0267 | 0.0267 |
Plasmodium vivax | bifunctional dihydrofolate reductase-thymidylate synthase, putative | 0.103 | 0.4267 | 1 |
Echinococcus multilocularis | thymidylate synthase | 0.0159 | 0.0267 | 0.0267 |
Echinococcus granulosus | dihydrofolate reductase | 0.2278 | 1 | 1 |
Plasmodium falciparum | bifunctional dihydrofolate reductase-thymidylate synthase | 0.103 | 0.4267 | 1 |
Toxoplasma gondii | 3-oxo-5-alpha-steroid 4-dehydrogenase | 0.0377 | 0.127 | 0.2977 |
Trypanosoma cruzi | dihydrofolate reductase-thymidylate synthase | 0.103 | 0.4267 | 1 |
Toxoplasma gondii | bifunctional dihydrofolate reductase-thymidylate synthase | 0.103 | 0.4267 | 1 |
Brugia malayi | thymidylate synthase | 0.0159 | 0.0267 | 0.0267 |
Trichomonas vaginalis | 3-oxo-5-alpha-steroid 4-dehydrogenase, putative | 0.0377 | 0.127 | 1 |
Mycobacterium leprae | DIHYDROFOLATE REDUCTASE DFRA (DHFR) (TETRAHYDROFOLATE DEHYDROGENASE) | 0.2278 | 1 | 1 |
Brugia malayi | Dihydrofolate reductase | 0.2278 | 1 | 1 |
Echinococcus multilocularis | dihydrofolate reductase | 0.2278 | 1 | 1 |
Mycobacterium tuberculosis | Dihydrofolate reductase DfrA (DHFR) (tetrahydrofolate dehydrogenase) | 0.2278 | 1 | 1 |
Mycobacterium ulcerans | dihydrofolate reductase DfrA | 0.2278 | 1 | 1 |
Chlamydia trachomatis | dihydrofolate reductase | 0.2278 | 1 | 0.5 |
Trypanosoma brucei | 3-oxo-5-alpha-steroid 4-dehydrogenase-like, putative | 0.0377 | 0.127 | 0.2977 |
Treponema pallidum | folylpolyglutamate synthetase (folC) | 0.0101 | 0 | 0.5 |
Loa Loa (eye worm) | dihydrofolate reductase | 0.2278 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | uM | Inhibition of Cytochrome P450 17 from rat testicular microsome at 125 uM progesterone; No inhibition | ChEMBL. | 11063622 |
IC50 (binding) | 0 uM | Inhibition of Cytochrome P450 17 from rat testicular microsome at 125 uM progesterone; No inhibition | ChEMBL. | 11063622 |
IC50 (binding) | > 2.5 uM | Evaluated for the inhibitory activity towards Cytochrome P450 17 human enzyme using testicular microsome at 25 microM of substrate (progesterone) | ChEMBL. | 11063622 |
IC50 (binding) | > 2.5 uM | Evaluated for the inhibitory activity towards Cytochrome P450 17 human enzyme using testicular microsome at 25 microM of substrate (progesterone) | ChEMBL. | 11063622 |
IC50 (binding) | = 3.2 uM | Evaluated for the inhibitory activity against human steroid 5-alpha-reductase type 2 from human BPH tissue at 210 nM of testosterone | ChEMBL. | 11063622 |
IC50 (binding) | = 3.2 uM | Evaluated for the inhibitory activity against human steroid 5-alpha-reductase type 2 from human BPH tissue at 210 nM of testosterone | ChEMBL. | 11063622 |
IC50 (binding) | > 10 uM | Evaluated for the inhibitory activity against human steroid 5-alpha-reductase type I in human DU-145 cell assay at 5 nM of androstenedione | ChEMBL. | 11063622 |
IC50 (binding) | > 10 uM | Evaluated for the inhibitory activity against human steroid 5-alpha-reductase type I in human DU-145 cell assay at 5 nM of androstenedione | ChEMBL. | 11063622 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.